Novartis AG

Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial (2021) Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials (2021) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, et al. Journal article Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies (2021) Schett G, Baraliakos X, Van Den Bosch F, Deodhar A, Ostergaard M, Das Gupta A, Mpofu S, et al. Journal article Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article Trotz einer großen Auswahl wirksame Medikamente: Psoriatiker scheinen immer noch untertherapiert zu sein (2021) Pilz AC, Zink A, Schielein MC, Hell K, Romer K, Hillmann E, Bäumer D, et al. Journal article LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY (2021) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) Boers M, Conaghan PG, Schett G, Mandl P, Naredo E, Van Den Bosch F, Burgos-Vargas R, et al. Conference contribution